Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Tenax Therapeutics, Inc./ 10-Q

Quarterly Report · 10-Q

Tenax Therapeutics, Inc.

TENXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 13, 2025Accepted Aug 13, 2025, 4:22 PM EDTCIK 34956Accession 0000950170-25-108063
View company →Permanent SEC source ↗
Share

Company context

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Current securities

TENXNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G/A - filed by SPHERA FUNDS MANAGEMENT LTD. regarding TENAX THERAPEUTICS, INC.Oct 13, 2026
  2. Other EventsOct 8, 2026
  3. SCHEDULE 13G/A - filed by ING GROEP NV regarding TENAX THERAPEUTICS, INC.Sep 11, 2026
  4. Regulation FD DisclosureSep 9, 2026
  5. SCHEDULE 13G - filed by ADAR1 Capital Management, LLC regarding TENAX THERAPEUTICS, INC.Sep 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.